On demand webinar: Staring into the abyss? Navigating the NHS post-election
Regardless of the colour of the next UK government that emerges as a result of the May election, the £30–50bn NHS budget chasm is the abyss that all the parties fear in respect to its threat to quality health service delivery and re-election.
With political backs to the abyss, no hostages will be taken. It is not unrealistic to expect a well co-ordinated and concerted offence by politicians and patient organisations alike on industry pricing of innovative speciality and rare diseases medicines.
With this scenario in mind, pharmaphorum is once again working with IMS Health to bring you expert insight into what this means for the UK health system and more specifically market access for specialist treatments in the post-election environment.
Angela McFarlane, Senior Principal, IMS Health Local Market Access, Dr Anthony Grosso, Principal Pharmacist, National Hospital for Neurology and Neurosurgery (NHNN) and Sheela Upadhyaya, previously a NHS Senior Manager with over 17 years of experience in the delivery of services and in commissioning of highly specialised services for rare and ultra rare conditions, combine with pharmaphorum’s Paul Tunnah to deliver an accurate analysis and frontline insight into how the already complex roadmap for access is about to change again.
This one-hour event will include analysis of informed predictions, which include:
- The NICE HTA criteria will get tougher post end-to-end review (IMMTreV)
- NICE and NHS England will join forces to streamline access pre/post NICE
- Risk at local level will be shifted to providers under the new marginal tariff arrangements, which could indeed see a close to the CDF as the PbR excluded drugs list becomes a thing of a glorious past
- Provider baselines will take the strain of innovation – the tough decisions will be softened by a drive to really accelerate uptake of NICE approved medicines
How can industry prepare for these changes in what is already a tough and complex environment?
To view, please click here or on the webinar widget below.
Angela McFarlane, Senior Principal, IMS Health Local Market Access
Prior to its acquisition by IMS Health in October 2013, Angela McFarlane was the founding Director of HGS Europe, a company at the forefront of the UK Market Access environment for over 15 years. The acquisition of HGS by IMS Health enabled the companies to build on their reputation for payer-centric Market Access solutions informed by a unique and extensive network of over 1,000 NHS Associates, enabling the programmes delivered to be truly valued by payer audiences. The synergy between IMS Health Real World Evidence, data and market access solutions are benefitting both existing and new clients, particularly in the growing rare disease and speciality medicine markets. Angela’s career has also included being Marketing Director for specialist Provider hospital, Surgicare, and 9 years at Merck Sharp and Dohme and Bristol Myers Squibb, where she held a number of sales and marketing management positions. During that period she launched for two ACEIs and a statin.
Dr Anthony Grosso, Principal Pharmacist, NHNN
Dr Anthony Grosso has a long-standing interest in drug policy, access and reimbursement. For over a decade, Anthony has been Principal Pharmacist at UCL Hospitals where he has overseen medicines management for the Trust and has been special advisor to the London Procurement Partnership on branded medicines. Anthony now consults for the pharmaceutical industry whilst retaining a part-time position heading up the pharmacy service at the National Hospital for Neurology & Neurosurgery, which has a >£35M annual medicines expenditure.
Dr Paul Tunnah, CEO, pharmaphorum
Paul Tunnah is CEO and Founder of pharmaphorum media, which facilitates productive engagement for pharma, bringing healthcare together to drive medical innovation. It combines industry-leading content and social media engagement services with the globally recognised news, information and insight portal pharmaphorum.com, working with pharmaceutical companies, service providers and broader healthcare organisations to help communicate their thought leadership and connect them with relevant stakeholders.
Sheela Upadhyaya, prev. NHS-E Highly specialised programme of care lead
Sheela Upadhyaya has over 17 years of experience in the delivery of services in the acute setting along with commissioning of highly specialised services for rare and ultra-rare conditions. Her biggest successes have been in delivering national high cost drugs and homecare tenders, working with multiples stakeholders, patients, clinicians and the Commercial Medicines Unit. She currently supports a number of James Lind Alliance Priority Setting Partnerships as Chair and uses this process platform as a tool to learn more about different conditions/diseases.
* When you click to register for this webinar you will be taken to a website run by BrightTalk who host the webinar and gather your registration data.
This data may then be passed to pharmaphorum media limited, and in turn passed to the company(ies) we are partnering with to bring you the webinar. This data may be used by us and them for occasional marketing purposes. It will not be shared with any further third parties.
By clicking to register for this webinar you give consent for any data you provide to be used in this way.
If at any point you no longer wish to be contacted based on the information you provide during the registration for this webinar, please send an email to firstname.lastname@example.org requesting that your information is deleted in accordance with the General Data Protection Regulation.